BAX Stock Overview
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Baxter International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.50 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.64 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -36.63% |
| 5 Year Change | -22.14% |
| Change since IPO | 104.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAX | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | -0.8% |
| 1Y | 0% | 7.2% | -2.2% |
Return vs Industry: BAX underperformed the Swiss Medical Equipment industry which returned 10% over the past year.
Return vs Market: BAX exceeded the Swiss Market which returned -3.4% over the past year.
Price Volatility
| BAX volatility | |
|---|---|
| BAX Average Weekly Movement | 0% |
| Medical Equipment Industry Average Movement | 3.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: BAX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1931 | 60,000 | Joe Almeida | www.baxter.com |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.
Baxter International Inc. Fundamentals Summary
| BAX fundamental statistics | |
|---|---|
| Market cap | CHF17.34b |
| Earnings (TTM) | CHF192.06m |
| Revenue (TTM) | CHF13.04b |
90.3x
P/E Ratio1.3x
P/S RatioIs BAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAX income statement (TTM) | |
|---|---|
| Revenue | US$15.28b |
| Cost of Revenue | US$9.38b |
| Gross Profit | US$5.90b |
| Other Expenses | US$5.68b |
| Earnings | US$225.00m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 08, 2024
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 38.63% |
| Net Profit Margin | 1.47% |
| Debt/Equity Ratio | 202.0% |
How did BAX perform over the long term?
See historical performance and comparison